Woodline Partners’s Oruka Therapeutics ORKA Stock Holding History

Woodline Partners’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.1M	Sell	285,247 -289,635	-50%	-$19.3M	0.08%	304
2026 Q1	$28.2M	Buy	574,882 +329	+0.1%	+$11.4K	0.11%	257
2025 Q4	$17.4M	Buy	574,553 +223	+0%	+$6.21K	0.07%	341
2025 Q3	$11M	Buy	574,330 +183,426	+47%	+$2.72M	0.05%	422
2025 Q2	$4.38M	Buy	390,904 +100	+0%	+$1.04K	0.02%	588
2025 Q1	$4.01M	Sell	390,804 -165	-0%	-$2.06K	0.03%	558
2024 Q4	$7.58M	Buy	390,969 +174	+0%	+$4.25K	0.05%	408
2024 Q3	$9.58M	Buy	+390,795	New	+$13.6M	0.08%	299

Other funds holding ORKA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Woodline Partners's ORKA Position: Q2 2026 in Review

Woodline Partners reduced its Oruka Therapeutics (ORKA) stake by 50% in Q2 2026, selling an estimated $19.3M and leaving 285,247 shares worth $27.1M. The position accounts for 0.08% of the portfolio, ranked #304.

Woodline Partners first reported a position in ORKA in Q3 2024 and has held it in 8 quarters since. The position peaked at $28.2M in Q1 2026. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

Woodline Partners held 285,247 shares of Oruka Therapeutics worth $27.1M as of Q2 2026.
Woodline Partners sold 289,635 Oruka Therapeutics shares in Q2 2026, an estimated $19.3M.
Oruka Therapeutics made up 0.08% of Woodline Partners's portfolio in Q2 2026, its #304 holding.
Woodline Partners first reported a position in Oruka Therapeutics in Q3 2024 and has held it in 8 quarters since.
Woodline Partners's Oruka Therapeutics position peaked at $28.2M in Q1 2026.
255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.